Biological Skin Substitutes Market - By Type (Human Donor Tissue-derived, Acellular Animal-derived, Tissue-Engineered, Biosynthetic), Application (Acute & Chronic Wound), End-use (Hospital, ASC)

Description

List of Tables

Global Biological Skin Substitutes Market will register 8.4% CAGR from 2023 to 2032, propelled by the emergence of personalized medicine and the development of innovative products. As research advances, novel skin substitutes with enhanced therapeutic properties are introduced, catering to diverse patient needs. For instance, in 2023, the European Commission granted approval to Secukinumab (Cosentyx) for treating adults with active, moderate-to-severe hidradenitis suppurativa. This approval signifies a positive stride for the biological skin substitutes industry, aligning with the trend of developing innovative solutions like secukinumab (Cosentyx) to address specific dermatological conditions. The trend toward personalized medicine further amplifies demand as tailored solutions become integral to addressing specific skin conditions. This synergy of innovation and personalized approaches will drive market expansion.

The biological skin substitutes market is bifurcated based on type, application, and region.

The chronic wounds segment will garner substantial gains through 2032. This prominence stems from the rising incidence of chronic wounds worldwide, driven by factors such as aging populations and the prevalence of diabetes. Biological skin substitutes offer effective therapeutic solutions for these persistent wounds, addressing the unmet medical needs associated with their management. As a result, the chronic wounds segment will play a pivotal role in driving market growth and innovation.

The biological skin substitutes industry size from the acellular animal-derived products segment will capture a remarkable share by 2032, attributed to their compatibility with human tissue, providing a scaffold for tissue regeneration. With their ability to facilitate wound healing and reduce scarring, acellular animal-derived products meet the growing demand for advanced and effective skin substitutes. This segment's prominence underscores the significance of natural biomaterials in addressing diverse medical needs and fostering innovation in the biological skin substitutes industry.

Asia-Pacific biological skin substitutes market will grow at a notable CAGR from 2023 to 2032, driven by a combination of factors, including a rising awareness of advanced medical treatments, increasing healthcare investments, and a growing patient population. As the region witnesses technological advancements and a surge in healthcare infrastructure, Asia-Pacific will emerge as a key contributor to the biological skin substitutes market outlook, meeting the escalating demand for innovative wound care solutions.

Product Code: 6964

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & workings
1.3 Forecast calculations
1.4 Data Sources
- 1.4.1 Primary
- 1.4.2 Secondary
  - 1.4.2.1 Paid sources
  - 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global biological skin substitutes market 360 degree synopsis, 2018 - 2032
2.2 Regional trends
2.3 Type trends
2.4 Application trends
2.5 End-use trends

Chapter 3 Biological Skin Substitutes Industry Insights

3.1 COVID- 19 impact analysis
3.2 Industry ecosystem analysis
3.3 Technology landscape
3.4 Regulatory landscape
3.5 Industry impact forces
- 3.5.1 Growth drivers
  - 3.5.1.1 Increasing prevalence of chronic wounds
  - 3.5.1.2 Rising number of burn & trauma cases
  - 3.5.1.3 Growing adoption of wound care facilities
  - 3.5.1.4 Technological advancements in regenerative medicine
- 3.5.2 Industry pitfalls & challenges
  - 3.5.2.1 Adverse side effects associated with biological skin substitutes
  - 3.5.2.2 Lack of reimbursement policies
3.6 Growth potential analysis
- 3.6.1 By type
- 3.6.2 By application
- 3.6.3 By end-use
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
- 4.1.1 Organogenesis Inc
- 4.1.2 Smith & Nephew plc
- 4.1.3 MiMedx Group, Inc.
4.2 Competitive analysis of major market players, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic outlook matrix, 2022

Chapter 5 Biological Skin Substitutes Market Size and Forecast, By Type, 2018-2032 (USD Million)

5.1 Key trends, by type
5.2 Human donor tissue-derived products
5.3 Acellular animal-derived products
5.4 Tissue-engineered skin products
5.5 Biosynthetic skin products

Chapter 6 Biological Skin Substitutes Market Size and Forecast, By Application, 2018-2032 (USD Million)

6.1 Key trends, by application
6.2 Acute wounds
6.3 Chronic wounds
6.4 Other applications

Chapter 7 Biological Skin Substitutes Market Size and Forecast, By End-use, 2018-2032 (USD Million)

7.1 Key trends, by end-use
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Specialty clinics
7.5 Other end-users

Chapter 8 Biological Skin Substitutes Market Size and Forecast, By Region, 2018-2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Organogenesis Inc
9.2 Smith & Nephew plc
9.3 MiMedx Group, Inc.
9.4 Misonix, Inc.(Bioventus)
9.5 Avita Medical
9.6 Stratatech Corporation (Mallinckrodt Pharmaceuticals)
9.7 BioTissue
9.8 Aroa Biosurgery
9.9 ProgenaCare
9.10 Mimedx Group (MiMedx Group, Inc.)
9.11 Tissue Regenix
9.12 Stryker
9.13 Vericel Corporation
9.14 Integra LifeSciences